English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#tnbc search results

IntensityInc's profile picture. Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies. Nasdaq: $INTS
Intensity Therapeutics
@IntensityInc
Dec 11

$INTS is presenting two posters at @SABCSSanAntonio. PS5-08-16 shares early Ph2 INVINCIBLE 4 #TNBC data showing favorable safety, with #INT2306 patients reporting 50% fewer grade 3+ adverse events vs standard neoadjuvant chemo. PS4-10-15 outlines a potential Ph3 study design

IntensityInc's tweet image. $INTS is presenting two posters at @SABCSSanAntonio. PS5-08-16 shares early Ph2 INVINCIBLE 4 #TNBC data showing favorable safety, with #INT2306 patients reporting 50% fewer grade 3+ adverse events vs standard neoadjuvant chemo. PS4-10-15 outlines a potential Ph3 study design
3
6
31
4
6K
ozdogan_md's profile picture. Oncologist. Cancer treatment & care in Turkey. Current advances, future directions and second opinion... Let's create a society which is not afraid of cancer!
Mustafa Özdoğan, MD
@ozdogan_md
Jan 15

First-line metastatic TNBC has officially changed! The key question is no longer “chemo or not?” It’s which ADC, for which patient, with which toxicity trade-off. Welcome to the ADC-first era in metastatic TNBC. #ASCO #ESMO #TNBC #BreastCancer #ADC #Sacituzumab #DatoDXd

ozdogan_md's tweet image. First-line metastatic TNBC has officially changed! The key question is no longer “chemo or not?” It’s which ADC, for which patient, with which toxicity trade-off. Welcome to the ADC-first era in metastatic TNBC. #ASCO #ESMO #TNBC #BreastCancer #ADC #Sacituzumab #DatoDXd
1
8
15
5
704
DFCI_BreastOnc's profile picture. Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Apr 10

Exploring new strategies in #TNBC with Alexandra Indeglia, PhD who discussed targeting transcriptional drivers of plasticity and resistant cell states in #TripleNegativeBreastCancer at the @df_hcc #BreastAndGynecologicCancerSymposium.

DFCI_BreastOnc's tweet image. Exploring new strategies in #TNBC with Alexandra Indeglia, PhD who discussed targeting transcriptional drivers of plasticity and resistant cell states in #TripleNegativeBreastCancer at the @df_hcc #BreastAndGynecologicCancerSymposium.
0
2
10
0
474
DFCI_BreastOnc's profile picture. Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Feb 27

ICYMI 👉Here are recent results from the ASCENT-04 trial published in @NEJM. 👉pubmed.ncbi.nlm.nih.gov/41564397/ The study found that among patients with previously untreated, PD-L1+ advanced #TNBC, sacituzumab govitecan plus pembrolizumab resulted in longer PFS than chemotherapy plus

DFCI_BreastOnc's tweet image. ICYMI 👉Here are recent results from the ASCENT-04 trial published in @NEJM. 👉pubmed.ncbi.nlm.nih.gov/41564397/ The study found that among patients with previously untreated, PD-L1+ advanced #TNBC, sacituzumab govitecan plus pembrolizumab resulted in longer PFS than chemotherapy plus
DFCI_BreastOnc's tweet image. ICYMI 👉Here are recent results from the ASCENT-04 trial published in @NEJM. 👉pubmed.ncbi.nlm.nih.gov/41564397/ The study found that among patients with previously untreated, PD-L1+ advanced #TNBC, sacituzumab govitecan plus pembrolizumab resulted in longer PFS than chemotherapy plus
DFCI_BreastOnc's tweet image. ICYMI 👉Here are recent results from the ASCENT-04 trial published in @NEJM. 👉pubmed.ncbi.nlm.nih.gov/41564397/ The study found that among patients with previously untreated, PD-L1+ advanced #TNBC, sacituzumab govitecan plus pembrolizumab resulted in longer PFS than chemotherapy plus
0
7
21
9
2K
ChandrakanthMv's profile picture. Medical Oncologist (Breast • GU • GI) Simplifying Oncology for DoctorsI Building MV Onco I Head Academics | Narayana Health Kolkata
MV Chandrakanth
@ChandrakanthMv
Jan 20

• Gupta et al. (Carboplatin in TNBC, JCO 2025) • EFS missed, OS delivered • Not biology — statistics (events + power + time) • Negative primary ≠ negative drug #TNBC #BreastCancer #ClinicalTrials #Oncology #Stats #MVOnco

ChandrakanthMv's tweet image. • Gupta et al. (Carboplatin in TNBC, JCO 2025) • EFS missed, OS delivered • Not biology — statistics (events + power + time) • Negative primary ≠ negative drug #TNBC #BreastCancer #ClinicalTrials #Oncology #Stats #MVOnco
1
7
21
11
1K
Dr_ElvinaA's profile picture. Assoc. Prof. | Medical Oncologist | ESO Ambassador Fighting for hope, seeking truth, raising sons, crossing borders — reminding the world: life matters.
Elvina Almuradova
 @Dr_ElvinaA
Dec 23

PLANeT trial challenges how we dose immunotherapy in early TNBC: Low-dose pembrolizumab (50 mg q6w ×3) + NACT
→ Meaningful pCR improvement (+13.3%)
→ Efficacy signal comparable to KEYNOTE-522
→ No increase in grade ≥3 toxicity Smarter dosing matters. #TNBC #Immunotherapy

Dr_ElvinaA's tweet image. PLANeT trial challenges how we dose immunotherapy in early TNBC: Low-dose pembrolizumab (50 mg q6w ×3) + NACT
→ Meaningful pCR improvement (+13.3%)
→ Efficacy signal comparable to KEYNOTE-522
→ No increase in grade ≥3 toxicity Smarter dosing matters. #TNBC #Immunotherapy
2
11
47
20
3K
OncLive's profile picture. Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
OncLive.com
@OncLive
Nov 25

Early signals from the DB-1305 TROP-2 ADC show antitumor activity in heavily pretreated metastatic TNBC, with manageable TRAEs and no treatment-related deaths. @ErikaHamilton9 outlines next steps for combinations. 💡 Read more: hubs.li/Q03VHTRV0 #BreastCancer #TNBC

OncLive's tweet image. Early signals from the DB-1305 TROP-2 ADC show antitumor activity in heavily pretreated metastatic TNBC, with manageable TRAEs and no treatment-related deaths. @ErikaHamilton9 outlines next steps for combinations. 💡 Read more: hubs.li/Q03VHTRV0 #BreastCancer #TNBC
0
1
2
0
542
CheckOrphan's profile picture. CheckOrphan is the leading #news and information platform dedicated to #rarediseases and #orphandrugs
Rare Diseases
 @CheckOrphan
Feb 3

FDA Grants Priority Review to DATROWAY sBLA for First-Line Treatment of Metastatic Triple-Negative Breast Cancer - For More Information Visit shorturl.at/NaXsY @DaiichiSankyoUS #Breast_Cancer #TNBC

CheckOrphan's tweet image. FDA Grants Priority Review to DATROWAY sBLA for First-Line Treatment of Metastatic Triple-Negative Breast Cancer - For More Information Visit shorturl.at/NaXsY @DaiichiSankyoUS #Breast_Cancer #TNBC
2
0
0
0
182
OncLive's profile picture. Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
OncLive.com
@OncLive
Jan 4

MRD monitoring via ctDNA post-surgery may refine risk stratification in TNBC: MRD-positive patients without pCR face an 87% recurrence risk. 🩸 Learn more: hubs.li/Q03YCT030 #BreastCancerResearch #TNBC #HemeOnc

0
2
7
1
563
OncLive's profile picture. Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
OncLive.com
@OncLive
Jan 10

With strong survival gains already shown in ASCENT, attention is turning to sacituzumab govitecan as a potential frontline option for metastatic TNBC, including patients not eligible for immunotherapy. 🎯 Read more: hubs.li/Q03-55Yh0 #TNBC

0
0
1
0
398
DFCI_BreastOnc's profile picture. Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Jan 29

Erica Mayer, MD, MPH, (@elmayermd) discusses results of the phase 2 @TheTBCRC 056 trial evaluating neoadjuvant niraparib plus dostarlimab in patients with germline BRCA- or PALB2-mutated #TNBC. #TripleNegativeBreastCancer #BreastCancer healio.com/news/hematolog…

DFCI_BreastOnc's tweet card. SAN ANTONIO — In this video, Erica L. Mayer, MD, MPH, discusses results of the phase 2 TBCRC 056 trial evaluating neoadjuvant niraparib plus dostarlimab in patients with germline BRCA- or PALB2-mut...
VIDEO: Niraparib plus dostarlimab shows promise in BRCA , PALB2 mutated breast cancer
Source: healio.com
1
1
3
0
454
YaleCancer's profile picture. Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.
Yale Cancer Center
@YaleCancer
Apr 28

Innovative research from @yalepathology presented #AACR25 uses spatial profiling & machine learning to develop cost effective predictive biomarkers in #TNBC #breastcancer @tznaung @DavidRimm @YaleMBB @AACR @SmilowCancer

YaleCancer's tweet image. Innovative research from @yalepathology presented #AACR25 uses spatial profiling & machine learning to develop cost effective predictive biomarkers in #TNBC #breastcancer @tznaung @DavidRimm @YaleMBB @AACR @SmilowCancer
YaleCancer's tweet image. Innovative research from @yalepathology presented #AACR25 uses spatial profiling & machine learning to develop cost effective predictive biomarkers in #TNBC #breastcancer @tznaung @DavidRimm @YaleMBB @AACR @SmilowCancer
YaleCancer's tweet image. Innovative research from @yalepathology presented #AACR25 uses spatial profiling & machine learning to develop cost effective predictive biomarkers in #TNBC #breastcancer @tznaung @DavidRimm @YaleMBB @AACR @SmilowCancer
1
9
26
3
4K
DFCI_BreastOnc's profile picture. Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Feb 19

Register for the Spring #TNBC Symposium happening in Seville, Spain on April 10th, 2026! The in-person event is hosted by Dr. Luis de la Cruz, Dr. Fernando Henao and Dr. Ana Garrido-Castro 🟪Check out the program and register today! tacticsmd.net/actividad/spri…

DFCI_BreastOnc's tweet image. Register for the Spring #TNBC Symposium happening in Seville, Spain on April 10th, 2026! The in-person event is hosted by Dr. Luis de la Cruz, Dr. Fernando Henao and Dr. Ana Garrido-Castro 🟪Check out the program and register today! tacticsmd.net/actividad/spri…
0
5
7
1
691
DFCI_BreastOnc's profile picture. Patient-centered care, clinical trials & translational research on breast cancer @DanaFarber and @HarvardMed. Appts: 877-442-3324, Clinical trials: 877-338-7425
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Mar 4

Carol MacKenzie, faced #TripleNegativeBreastCancer with limited options – but then a clinical trial offered a new path. Her story shows how #AntibodyDrugConjugates are giving some patients renewed hope and more time. #TNBC #BreastCancer #ADCs @stolaney1 @nlinmd

DFCI_BreastOnc's tweet image. Carol MacKenzie, faced #TripleNegativeBreastCancer with limited options – but then a clinical trial offered a new path. Her story shows how #AntibodyDrugConjugates are giving some patients renewed hope and more time. #TNBC #BreastCancer #ADCs @stolaney1 @nlinmd
DFCI_BreastOnc's tweet image. Carol MacKenzie, faced #TripleNegativeBreastCancer with limited options – but then a clinical trial offered a new path. Her story shows how #AntibodyDrugConjugates are giving some patients renewed hope and more time. #TNBC #BreastCancer #ADCs @stolaney1 @nlinmd
DFCI_BreastOnc's tweet image. Carol MacKenzie, faced #TripleNegativeBreastCancer with limited options – but then a clinical trial offered a new path. Her story shows how #AntibodyDrugConjugates are giving some patients renewed hope and more time. #TNBC #BreastCancer #ADCs @stolaney1 @nlinmd
DFCI_BreastOnc's tweet image. Carol MacKenzie, faced #TripleNegativeBreastCancer with limited options – but then a clinical trial offered a new path. Her story shows how #AntibodyDrugConjugates are giving some patients renewed hope and more time. #TNBC #BreastCancer #ADCs @stolaney1 @nlinmd
2
4
13
1
805
YaleCancer's profile picture. Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.
Yale Cancer Center
@YaleCancer
May 13

Supporting #breastfeeding could reduce new diagnoses of #TNBC by up to 15% in Black women and 12% in White women according to a study led by Dr. Lajos Pusztai @YaleBreast. nature.com/articles/s4152… @SmilowCancer @YaleMed @YNHH @Nature_NPJ

YaleCancer's tweet card. npj Breast Cancer - Breastfeeding attributable fraction of triple negative breast cancer in the US
Breastfeeding attributable fraction of triple negative breast cancer in the US
Source: nature.com
2
4
7
0
1K
DAVAOnc's profile picture. DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
DAVA Oncology
 @DAVAOnc
Aug 22

ORR 23% with Emi-Le in B7-H4 high #TNBC (29% ≤4 prior lines); median PFS 16 wks vs 6–7 wks in B7-H4 low, OS not reached in select subgroups. Dr. Antonio Giordano (@antgiorda) of @DanaFarber presents Phase 1 data on anti-B7-H4 ADC at #DAVABreast. #BreastCancer

DAVAOnc's tweet image. ORR 23% with Emi-Le in B7-H4 high #TNBC (29% ≤4 prior lines); median PFS 16 wks vs 6–7 wks in B7-H4 low, OS not reached in select subgroups. Dr. Antonio Giordano (@antgiorda) of @DanaFarber presents Phase 1 data on anti-B7-H4 ADC at #DAVABreast. #BreastCancer
DAVAOnc's tweet image. ORR 23% with Emi-Le in B7-H4 high #TNBC (29% ≤4 prior lines); median PFS 16 wks vs 6–7 wks in B7-H4 low, OS not reached in select subgroups. Dr. Antonio Giordano (@antgiorda) of @DanaFarber presents Phase 1 data on anti-B7-H4 ADC at #DAVABreast. #BreastCancer
DAVAOnc's tweet image. ORR 23% with Emi-Le in B7-H4 high #TNBC (29% ≤4 prior lines); median PFS 16 wks vs 6–7 wks in B7-H4 low, OS not reached in select subgroups. Dr. Antonio Giordano (@antgiorda) of @DanaFarber presents Phase 1 data on anti-B7-H4 ADC at #DAVABreast. #BreastCancer
DAVAOnc's tweet image. ORR 23% with Emi-Le in B7-H4 high #TNBC (29% ≤4 prior lines); median PFS 16 wks vs 6–7 wks in B7-H4 low, OS not reached in select subgroups. Dr. Antonio Giordano (@antgiorda) of @DanaFarber presents Phase 1 data on anti-B7-H4 ADC at #DAVABreast. #BreastCancer
2
5
20
2
2K
OncLive's profile picture. Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
OncLive.com
@OncLive
Mar 14

Impressive 79% ORR achieved with dato-DXd + durvalumab in advanced TNBC, highlighting new hope for patients and clinicians. Explore the data: hubs.li/Q046QGN70 #oncology #TNBC

0
0
3
0
544
OncLive's profile picture. Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
OncLive.com
@OncLive
Feb 10

Stay ahead in #TNBC care. Join us for a 6-part series on the latest ADC clinical data, TROP-2 targets, and evolving standards for early-stage and metastatic disease. #BCSM Watch Now: hubs.li/Q0416hD_0

OncLive's tweet image. Stay ahead in #TNBC care. Join us for a 6-part series on the latest ADC clinical data, TROP-2 targets, and evolving standards for early-stage and metastatic disease. #BCSM Watch Now: hubs.li/Q0416hD_0
0
2
11
2
459
CheckOrphan's profile picture. CheckOrphan is the leading #news and information platform dedicated to #rarediseases and #orphandrugs
Rare Diseases
 @CheckOrphan
Apr 27

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer - For More Information Visit checkorphan.org/news/502047/ #CytoDyn #Rare_Diseases #TNBC #Breast_Cancer #Orphan_Drugs #Cancer_research #Cancer_Drugs

CheckOrphan's tweet image. CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer - For More Information Visit checkorphan.org/news/502047/ #CytoDyn #Rare_Diseases #TNBC #Breast_Cancer #Orphan_Drugs #Cancer_research #Cancer_Drugs
0
1
3
0
134
AlexisLeVee's profile picture. Breast medical oncologist and researcher @UCLA | Views my own
Alexis LeVee, MD
 @AlexisLeVee
Apr 26

Excited to share our @ASCO Educational Book article on updates in management of stage 2-3 #TNBC. In this article, we review: - Current standard of care for stage 2-3 TNBC - Novel investigational therapies and combination strategies, including ADCs, anti-VEGF therapies, dual

1
12
44
23
4K
CJTsaiMDPhD's profile picture. Lead, Allan & Ruth Kerbel Palliative RT/Oligomet Program (PROP) @PMcancercentre @RadMedPM @UHN. Via @MSKCancerCenter @MDAndersonNews. HN/skin/metastatic cancers
C. Jillian Tsai, MD, PhD
 @CJTsaiMDPhD
Apr 24

♀️🫶 Honored to join the discussion on biology-directed RT for MBC @GBCC_Korea - great exchange on trial design frameworks and upcoming studies incl. AVATAR2 (@TROGfightcancer), Clarity (@NRGonc), and S2511 (@SWOG). Time to push forward a dedicated trial for #TNBC?

CJTsaiMDPhD's tweet image. ♀️🫶 Honored to join the discussion on biology-directed RT for MBC @GBCC_Korea - great exchange on trial design frameworks and upcoming studies incl. AVATAR2 (@TROGfightcancer), Clarity (@NRGonc), and S2511 (@SWOG). Time to push forward a dedicated trial for #TNBC?
CJTsaiMDPhD's tweet image. ♀️🫶 Honored to join the discussion on biology-directed RT for MBC @GBCC_Korea - great exchange on trial design frameworks and upcoming studies incl. AVATAR2 (@TROGfightcancer), Clarity (@NRGonc), and S2511 (@SWOG). Time to push forward a dedicated trial for #TNBC?
CJTsaiMDPhD's tweet image. ♀️🫶 Honored to join the discussion on biology-directed RT for MBC @GBCC_Korea - great exchange on trial design frameworks and upcoming studies incl. AVATAR2 (@TROGfightcancer), Clarity (@NRGonc), and S2511 (@SWOG). Time to push forward a dedicated trial for #TNBC?
1
5
20
2
1K
sigtrans_sttt's profile picture. Signal Transduction and Targeted Therapy (STTT) | A Nature Portfolio Journal | Impact Factor 52.7 | CiteScore: 58.6 | Peer-reviewed | Open Access |
Signal Transduction and Targeted Therapy (STTT)
@sigtrans_sttt
Apr 22

The ncRNA-derived peptide 66CTG drives #TNBC growth by stabilizing c-Myc and upregulating Cyclin D1 via FBW7α interaction, revealing a novel #Oncogenic axis and potential #TherapeuticTarget. #BreastCancer #STTT #OpenAccess: doi.org/10.1038/s41392…

sigtrans_sttt's tweet image. The ncRNA-derived peptide 66CTG drives #TNBC growth by stabilizing c-Myc and upregulating Cyclin D1 via FBW7α interaction, revealing a novel #Oncogenic axis and potential #TherapeuticTarget. #BreastCancer #STTT #OpenAccess: doi.org/10.1038/s41392…
0
0
1
0
76
IntensityInc's profile picture. Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies. Nasdaq: $INTS
Intensity Therapeutics
@IntensityInc
Apr 21

$INTS recently shared a Phase 2 INVINCIBLE-4 update for INT230-6 in #TNBC. Preliminary observations showed higher pCR and fewer high-grade AEs vs SOC. Enrollment restart pending. Read more: bit.ly/4lpFI13 #ClinicalTrials

IntensityInc's tweet image. $INTS recently shared a Phase 2 INVINCIBLE-4 update for INT230-6 in #TNBC. Preliminary observations showed higher pCR and fewer high-grade AEs vs SOC. Enrollment restart pending. Read more: bit.ly/4lpFI13 #ClinicalTrials
0
1
11
1
417
PeerView's profile picture. Improving the knowledge, skills, and strategies that support clinical performance and patient outcomes through the provision of live and on-demand CE
PeerView
@PeerView
Apr 20

Are you ready to maximize clinical benefit for your patients with #TNBC and HR+, HER2- #BreastCancer? Watch this new PeerView activity for expert, data-driven insight on how TROP2-targeting ADCs are reshaping care! bit.ly/46XelF6 #Oncology #MedEd

PeerView's tweet card. See a new #TNBC and HR+, HER2- #BreastCancer activity via @PeerView #MedEd
TROP2-Targeting ADCs in the Forefront: Changing Standards and Best Practices in TNBC and HR+, HER2-...
Source: lrn.peerview.com
0
3
9
1
194
JoeyBagels's profile picture. UFA Fire Marshal Representative , Navy Seabee Veteran, NRA Range Safety Officer, EMT, CB10 member, SBG Coop BOD, TNLL Coach🇺🇸
Joe Connolly
 @JoeyBagels
Apr 20

Jake C #41 doing his thing !! #TNBC

JoeyBagels's tweet image. Jake C #41 doing his thing !! #TNBC
0
0
1
0
14
fulya_alkan_'s profile picture. Postdoctoral researcher @ Karmanos Cancer Institute, WSU, Detroit, MI
Fulya Koksalar Alkan
 @fulya_alkan_
Apr 17

Best scientific event of the year for me starting today! #AACR26 ! This year is more special! My work on the contribution of subtypes of neutrophils to systemic inflammatory in #TNBC brought me Scholar-in-Training Award! Visit the related work and contributions of our lab (below)

fulya_alkan_'s tweet image. Best scientific event of the year for me starting today! #AACR26 ! This year is more special! My work on the contribution of subtypes of neutrophils to systemic inflammatory in #TNBC brought me Scholar-in-Training Award! Visit the related work and contributions of our lab (below)
1
0
2
1
164
MammaryCell's profile picture. An online resource for mammary cell and breast cancer researchers. Part of the @STEMCELLTech Science News service.
Mammary Cell News
@MammaryCell
Apr 16

Integrative proteogenomic profiling enables robust prediction of chemotherapy resistance in #TNBC and identifies actionable biomarkers providing a framework for advancing personalized therapeutic strategies. 🧬@GenomeBiology | bit.ly/4csd2Rc

MammaryCell's tweet image. Integrative proteogenomic profiling enables robust prediction of chemotherapy resistance in #TNBC and identifies actionable biomarkers providing a framework for advancing personalized therapeutic strategies. 🧬@GenomeBiology | bit.ly/4csd2Rc
0
0
0
0
35
PatientWorthy's profile picture. We're a resource for engaging, informative content and rare patient news, well done.
Patient Worthy
 @PatientWorthy
Apr 15

Triple Negative Breast Cancer: A Breakthrough Treatment bit.ly/4txJybj Read now at PatientWorthy.com #PatientWorthy #TripleNegativeBreastCancer #TNBC

PatientWorthy's tweet image. Triple Negative Breast Cancer: A Breakthrough Treatment bit.ly/4txJybj Read now at PatientWorthy.com #PatientWorthy #TripleNegativeBreastCancer #TNBC
0
0
1
0
71
MDMercyMedia's profile picture. Founded in 1874, Mercy Medical Center in Baltimore, Maryland, is home to the nationally acclaimed Weinberg Center for Women's Health and Medicine.
MDMercy Media
 @MDMercyMedia
Apr 15

Triple-negative breast cancer (#TNBC) does not have the same receptors as most other types of #breastcancer. David Riseberg, M.D., Chief, Medical Oncology & Hematology at Mercy, appeared in-studio to discuss, on #WBAL-TV11's "The Woman's Doctor". @wbaltv11 wbaltv.com/article/mercy-…

MDMercyMedia's tweet card. Mercy Medical Center oncologist Dr. David Riseberg joins Jenyne to discuss triple-negative breast cancer, and research into why it is more common among African American patients.
Mercy Medical Center oncologist explains how triple-negative breast cancer develops
Source: wbaltv.com
0
0
0
0
60
CheckOrphan's profile picture. CheckOrphan is the leading #news and information platform dedicated to #rarediseases and #orphandrugs
Rare Diseases
 @CheckOrphan
Apr 14

Cellectar Biosciences Enrolls First Patient in Phase 1b Trial of CLR 125 for Triple-Negative Breast Cancer, Advancing Targeted Radioconjugate Therapy - For More Information Visit shorturl.at/vS0lp @CellectarBio #TNBC #Breast_Cancer #Orphan_Drugs #Rare_Diseases

CheckOrphan's tweet image. Cellectar Biosciences Enrolls First Patient in Phase 1b Trial of CLR 125 for Triple-Negative Breast Cancer, Advancing Targeted Radioconjugate Therapy - For More Information Visit shorturl.at/vS0lp @CellectarBio #TNBC #Breast_Cancer #Orphan_Drugs #Rare_Diseases
0
0
0
0
87
PTarantinoMD's profile picture. MD, PhD, Medical Oncologist | Clinical Fellow @DanaFarber | @Harvard. Associate Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs and good music.
Paolo Tarantino
@PTarantinoMD
Apr 14

Sacituzumab govitecan in metastatic #TNBC!

PTarantinoMD's tweet image. Sacituzumab govitecan in metastatic #TNBC!
3
6
44
6
3K
OAE_JCMT's profile picture. An open access journal indexed in ESCI and Scopus, IF: 1.0, 2024 CiteScore: 2.7 #CancerMetastasis #CancerTreatment #Oncology #Tumor #Cancer #MedED #Biomedicine
Journal of Cancer Metastasis and Treatment
 @OAE_JCMT
Apr 14

🚨 Deadline approaching | Call for Papers 🚨 JCMT Special Topic: Triple-Negative Breast Cancer: From Mechanisms to Translational Frontiers 📅 Deadline: 31 May 2026 👤 Prof. Gary J. Whitman (MDACC) 🔗 Submit: oaecenter.com/login?JournalI… #TNBC #Oncology #CancerResearch #JCMT

OAE_JCMT's tweet image. 🚨 Deadline approaching | Call for Papers 🚨 JCMT Special Topic: Triple-Negative Breast Cancer: From Mechanisms to Translational Frontiers 📅 Deadline: 31 May 2026 👤 Prof. Gary J. Whitman (MDACC) 🔗 Submit: oaecenter.com/login?JournalI… #TNBC #Oncology #CancerResearch #JCMT
0
0
1
0
95
MedicalwatchHQ's profile picture. Want practice changing updates in oncology/hematology? Get the https://t.co/3QM59zCovH weekly newsletter. #MedTwitter
Medical.watch
@MedicalwatchHQ
Apr 13

🚨 TNBC treatment is being redefined: ADCs take center stage New insights from the 2026 ASCO Educational Book highlight a paradigm shift in metastatic #TNBC —from chemotherapy → to targeted and immune-based strategies 🔍 Key updates: 🔵 PD-L1+ disease • Pembrolizumab + chemo

MedicalwatchHQ's tweet image. 🚨 TNBC treatment is being redefined: ADCs take center stage New insights from the 2026 ASCO Educational Book highlight a paradigm shift in metastatic #TNBC —from chemotherapy → to targeted and immune-based strategies 🔍 Key updates: 🔵 PD-L1+ disease • Pembrolizumab + chemo
1
7
12
3
861
LiAllenMD's profile picture. Medical Oncologist | The Vancouver Clinic, Legacy Cancer Institute. Creator of Oncology AI Lab — stress testing AI to separate the signal from noise
Allen Li MD
@LiAllenMD
Apr 13

The guidelines say sacituzumab + pembro is ready for first line PDL1+ stage IV TNBC, based on Ascent 04. Do you think the data actually supports that? Find out what the trial shows: youtube.com/shorts/xwERcbC… #ASCENT04 #TNBC #BreastCancer #Trodelvy

LiAllenMD's tweet card. Oncology AI Lab

youtube.com

YouTube

Oncology AI Lab

Source: youtube.com
0
0
0
0
183
News18TamilNadu's profile picture. மின்னல் வேகத்தில் பிரேக்கிங் நியூஸ் #நியூஸ்18தமிழ்நாடு News18 Tamil Nadu, Network18 Group caters to News & information to the Tamil viewers.
News18 Tamil Nadu
@News18TamilNadu
Apr 13

திமுக கூட்டணிக்கு தமிழக ஆயர் பேரவை ஆதரவு #TNBC #DMK #Election2026 #News18Taminadu | News18Tamil.com

News18TamilNadu's tweet image. திமுக கூட்டணிக்கு தமிழக ஆயர் பேரவை ஆதரவு #TNBC #DMK #Election2026 #News18Taminadu | News18Tamil.com
44
147
474
6
9K
tamil_nadu_news's profile picture. Breaking News24/7 Live News Latest News In Politics, Sports, Business & Cinema News Also follow Us
Tamil Nadu News 24/7
 @tamil_nadu_news
Apr 13

திமுக கூட்டணிக்கு தமிழக ஆயர் பேரவை ஆதரவு #TNBC | #DMK | #Election2026 | #ElectionWithPT | #TNElection

tamil_nadu_news's tweet image. திமுக கூட்டணிக்கு தமிழக ஆயர் பேரவை ஆதரவு #TNBC | #DMK | #Election2026 | #ElectionWithPT | #TNElection
0
0
0
0
25
CancerGrand's profile picture. Daring to solve some of the most complex challenges in cancer research |  Founded by: @CR_UK & @theNCI
Cancer Grand Challenges
@CancerGrand
Oct 9, 2024

TODAY IN @Nature 📢 #CancerGrandChallenges team SPECIFICANCER identifies a combination of inhibitors targeting epigenetic and oncogenic pathways, which drive differentiation to enable hijacking of tissue-specific cell death pathways in #TNBC. More 👉 bit.ly/483dO4E

CancerGrand's tweet image. TODAY IN @Nature 📢 #CancerGrandChallenges team SPECIFICANCER identifies a combination of inhibitors targeting epigenetic and oncogenic pathways, which drive differentiation to enable hijacking of tissue-specific cell death pathways in #TNBC. More 👉 bit.ly/483dO4E
1
4
9
2
1K
ChandrakanthMv's profile picture. Medical Oncologist (Breast • GU • GI) Simplifying Oncology for DoctorsI Building MV Onco I Head Academics | Narayana Health Kolkata
MV Chandrakanth
@ChandrakanthMv
Jan 20

• Gupta et al. (Carboplatin in TNBC, JCO 2025) • EFS missed, OS delivered • Not biology — statistics (events + power + time) • Negative primary ≠ negative drug #TNBC #BreastCancer #ClinicalTrials #Oncology #Stats #MVOnco

ChandrakanthMv's tweet image. • Gupta et al. (Carboplatin in TNBC, JCO 2025) • EFS missed, OS delivered • Not biology — statistics (events + power + time) • Negative primary ≠ negative drug #TNBC #BreastCancer #ClinicalTrials #Oncology #Stats #MVOnco
1
7
21
11
1K
IntensityInc's profile picture. Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies. Nasdaq: $INTS
Intensity Therapeutics
@IntensityInc
Dec 11

$INTS is presenting two posters at @SABCSSanAntonio. PS5-08-16 shares early Ph2 INVINCIBLE 4 #TNBC data showing favorable safety, with #INT2306 patients reporting 50% fewer grade 3+ adverse events vs standard neoadjuvant chemo. PS4-10-15 outlines a potential Ph3 study design

IntensityInc's tweet image. $INTS is presenting two posters at @SABCSSanAntonio. PS5-08-16 shares early Ph2 INVINCIBLE 4 #TNBC data showing favorable safety, with #INT2306 patients reporting 50% fewer grade 3+ adverse events vs standard neoadjuvant chemo. PS4-10-15 outlines a potential Ph3 study design
3
6
31
4
6K
fredhutch's profile picture. Making life beyond cancer a reality.
Fred Hutch Cancer Center
 @fredhutch
Apr 17, 2025

Fred Hutch translational researcher Dr. Kevin Cheung just received a $2M Breakthrough Award from the U.S. DoD’s Congressionally Directed Medical Research Programs, or CDMRP, to investigate a newly discovered pathway involving triple negative breast cancer, or #TNBC. 1/5

fredhutch's tweet image. Fred Hutch translational researcher Dr. Kevin Cheung just received a $2M Breakthrough Award from the U.S. DoD’s Congressionally Directed Medical Research Programs, or CDMRP, to investigate a newly discovered pathway involving triple negative breast cancer, or #TNBC. 1/5
1
2
5
3
875
tooniversal's profile picture. Imaginative, energetic, and engaging creator with comedic tendencies | 🔴LIVE M-F starting @ 8:30am ET | 📧info@tooniversal.tv
Toon
 @tooniversal
Oct 27, 2024

Throwback to my carved Oogie Boogie watermelon 🎃🍉 #Halloween #TNBC #NightmareBeforeChristmas

tooniversal's tweet image. Throwback to my carved Oogie Boogie watermelon 🎃🍉 #Halloween #TNBC #NightmareBeforeChristmas
1
1
21
0
611
DAVAOnc's profile picture. DAVA Oncology is a strategic consulting company committed to delivering high quality oncology education and expanding access novel cancer therapies.
DAVA Oncology
 @DAVAOnc
Aug 22

BT8009 in #TNBC! Dr. Jordi Rodon (@MDAndersonNews) shares Phase I data; ORR 63% in NECTIN4-amplified breast cancer (5/8) vs 14% overall, 57% in NECTIN4-amplified TNBC (4/7) with 100% DCR. Bicycle-based ADC shows biomarker-linked activity. #BreastCancer #DAVABreast

DAVAOnc's tweet image. BT8009 in #TNBC! Dr. Jordi Rodon (@MDAndersonNews) shares Phase I data; ORR 63% in NECTIN4-amplified breast cancer (5/8) vs 14% overall, 57% in NECTIN4-amplified TNBC (4/7) with 100% DCR. Bicycle-based ADC shows biomarker-linked activity. #BreastCancer #DAVABreast
DAVAOnc's tweet image. BT8009 in #TNBC! Dr. Jordi Rodon (@MDAndersonNews) shares Phase I data; ORR 63% in NECTIN4-amplified breast cancer (5/8) vs 14% overall, 57% in NECTIN4-amplified TNBC (4/7) with 100% DCR. Bicycle-based ADC shows biomarker-linked activity. #BreastCancer #DAVABreast
DAVAOnc's tweet image. BT8009 in #TNBC! Dr. Jordi Rodon (@MDAndersonNews) shares Phase I data; ORR 63% in NECTIN4-amplified breast cancer (5/8) vs 14% overall, 57% in NECTIN4-amplified TNBC (4/7) with 100% DCR. Bicycle-based ADC shows biomarker-linked activity. #BreastCancer #DAVABreast
1
4
15
2
6K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Dec 24

Huge congrats to @batraatulonc & the stellar team at @aiims_newdelhi on publication of the #PLANeT trial (chemo +/- low dose pembro in #TNBC) in @Annals_Oncology. A Herculean effort done at an amazing pace, with key implications that could extend across other areas in #oncology.

montypal's tweet image. Huge congrats to @batraatulonc & the stellar team at @aiims_newdelhi on publication of the #PLANeT trial (chemo +/- low dose pembro in #TNBC) in @Annals_Oncology. A Herculean effort done at an amazing pace, with key implications that could extend across other areas in #oncology.
batraatulonc's profile picture. Medical Oncologist & Clinical Researcher| AIIMS, New Delhi| Breast Cancer| Genitourinary Cancers| Supportive Care|
Atul Batra
 @batraatulonc
Dec 23

Delighted to share that the full paper of PLANeT trial is now available online in @Annals_Oncology We demonstrated that pembrolizumab dose as low as 50 mg every 6 weeks led to an improvement in PCR rates by 13.3%. @hoperugo @montypal @neerajaiims @PTarantinoMD @dradhiparora

7
20
58
3
15K
5
12
50
2
7K
scisignal's profile picture. Science Signaling offers researchers the most up-to-date resource for groundbreaking research and commentary in the dynamic field of cellular signaling.
Science Signaling
 @scisignal
Feb 13

A team of researchers has discovered how an RNA promotes the growth of triple-negative breast cancer (#TNBC) by activating two distinct molecular pathways and identified a new combination treatment that suppresses TNBC in culture. @BIDMChealth scim.ag/3ZADrpW

scisignal's tweet image. A team of researchers has discovered how an RNA promotes the growth of triple-negative breast cancer (#TNBC) by activating two distinct molecular pathways and identified a new combination treatment that suppresses TNBC in culture. @BIDMChealth scim.ag/3ZADrpW
1
0
3
0
439
OncoAlert's profile picture. 🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
OncoAlert
@OncoAlert
May 23

NEWS FROM INDUSTRY: Source Business Wire Update ASCENT-03 The Phase 3 ASCENT-03 trial sees sacituzumab govitecan-hziy improves progression-free survival compared to standard chemotherapy in patients with first-line metastatic triple-negative #BreastCancer (m #TNBC ) who are

OncoAlert's tweet image. NEWS FROM INDUSTRY: Source Business Wire Update ASCENT-03 The Phase 3 ASCENT-03 trial sees sacituzumab govitecan-hziy improves progression-free survival compared to standard chemotherapy in patients with first-line metastatic triple-negative #BreastCancer (m #TNBC ) who are
0
18
31
5
16K
JaniceTNBCmets's profile picture. Mom/Nana/Wife TNBC 2011👉🏻mTNBC 2016 | 🚫counted in #SEER | 🦄 NED 11/2016🦄 | Research & P2P pt adv | #knowledgeispower 💡
Janice Cowden
 @JaniceTNBCmets
Oct 2, 2024

Day # 2 of #BreastCancerACTIONMonth - Facts-a-Day from @metavivor Dx stage I tnbc 2011 no lymph node involvement, w. a Stage IV #metastatic #TNBC recurrence 5 yrs later in 2016, w. mets to distant lymph nodes (chest wall & contralateral hilar). Thanks to a proactive Med Onc, a

JaniceTNBCmets's tweet image. Day # 2 of #BreastCancerACTIONMonth - Facts-a-Day from @metavivor Dx stage I tnbc 2011 no lymph node involvement, w. a Stage IV #metastatic #TNBC recurrence 5 yrs later in 2016, w. mets to distant lymph nodes (chest wall & contralateral hilar). Thanks to a proactive Med Onc, a
0
3
12
0
598
OncoAlert's profile picture. 🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
OncoAlert
@OncoAlert
Feb 5, 2025

Day3⃣ #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4aUryQA @hoperugo 🇺🇸 of UCSF Covering Advanced #TNBC : Year in Review REGISTER NOW for a Live chat with Dr. Rugo In 2024, practice-changing data in triple-negative breast cancer (TNBC) supports

OncoAlert's tweet image. Day3⃣ #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4aUryQA @hoperugo 🇺🇸 of UCSF Covering Advanced #TNBC : Year in Review REGISTER NOW for a Live chat with Dr. Rugo In 2024, practice-changing data in triple-negative breast cancer (TNBC) supports
OncoAlert's tweet image. Day3⃣ #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4aUryQA @hoperugo 🇺🇸 of UCSF Covering Advanced #TNBC : Year in Review REGISTER NOW for a Live chat with Dr. Rugo In 2024, practice-changing data in triple-negative breast cancer (TNBC) supports
OncoAlert's tweet image. Day3⃣ #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4aUryQA @hoperugo 🇺🇸 of UCSF Covering Advanced #TNBC : Year in Review REGISTER NOW for a Live chat with Dr. Rugo In 2024, practice-changing data in triple-negative breast cancer (TNBC) supports
OncoAlert's tweet image. Day3⃣ #OncoAlertColloquium 🚨 #BreastCancer REGISTER for FREE HERE👉 buff.ly/4aUryQA @hoperugo 🇺🇸 of UCSF Covering Advanced #TNBC : Year in Review REGISTER NOW for a Live chat with Dr. Rugo In 2024, practice-changing data in triple-negative breast cancer (TNBC) supports
0
14
23
1
2K
LabWaggoner's profile picture. Research lab of Dr. Stephen Waggoner. Opinions expressed are Dr. Waggoner's alone and not on behalf of lab staff or employer. @labwaggoner.bsky.social
Waggoner Lab
 @LabWaggoner
Feb 18

Automated discernment of prognostic spatial features of #TNBC specific to cell interactions at the tumor border or metastatic site @NatureCancer @Stanford @MikeAngeloLab @NoahGreenwald @JoleneRanek nature.com/articles/s4301… nature.com/articles/s4301… nature.com/articles/s4301…

LabWaggoner's tweet image. Automated discernment of prognostic spatial features of #TNBC specific to cell interactions at the tumor border or metastatic site @NatureCancer @Stanford @MikeAngeloLab @NoahGreenwald @JoleneRanek nature.com/articles/s4301… nature.com/articles/s4301… nature.com/articles/s4301…
0
1
6
4
575
Dr_ElvinaA's profile picture. Assoc. Prof. | Medical Oncologist | ESO Ambassador Fighting for hope, seeking truth, raising sons, crossing borders — reminding the world: life matters.
Elvina Almuradova
 @Dr_ElvinaA
Dec 23

PLANeT trial challenges how we dose immunotherapy in early TNBC: Low-dose pembrolizumab (50 mg q6w ×3) + NACT
→ Meaningful pCR improvement (+13.3%)
→ Efficacy signal comparable to KEYNOTE-522
→ No increase in grade ≥3 toxicity Smarter dosing matters. #TNBC #Immunotherapy

Dr_ElvinaA's tweet image. PLANeT trial challenges how we dose immunotherapy in early TNBC: Low-dose pembrolizumab (50 mg q6w ×3) + NACT
→ Meaningful pCR improvement (+13.3%)
→ Efficacy signal comparable to KEYNOTE-522
→ No increase in grade ≥3 toxicity Smarter dosing matters. #TNBC #Immunotherapy
2
11
47
20
3K
scisignal's profile picture. Science Signaling offers researchers the most up-to-date resource for groundbreaking research and commentary in the dynamic field of cellular signaling.
Science Signaling
 @scisignal
Aug 20

Analyzing #TNBC cells, a team finds the transcription factor Hox-C12 supports metastasis by connecting beta2-ARs to a calcium-cAMP loop and show that HOXC12 expression correlates with worse survival in patients. @MIPS_Australia @Dr_MLHalls @TerranceLamm scim.ag/45nKIgw

scisignal's tweet image. Analyzing #TNBC cells, a team finds the transcription factor Hox-C12 supports metastasis by connecting beta2-ARs to a calcium-cAMP loop and show that HOXC12 expression correlates with worse survival in patients. @MIPS_Australia @Dr_MLHalls @TerranceLamm scim.ag/45nKIgw
0
1
5
1
398
PttvNewsX's profile picture. Puthiya Thalaimurai TV (Tamil: புதிய தலைமுறை டிவி) is a 24x7 live news channel
PttvOnlinenews
@PttvNewsX
Apr 13

திமுக கூட்டணிக்கு தமிழக ஆயர் பேரவை ஆதரவு #TNBC | #DMK | #Election2026 | #ElectionWithPT | #TNElection

PttvNewsX's tweet image. திமுக கூட்டணிக்கு தமிழக ஆயர் பேரவை ஆதரவு #TNBC | #DMK | #Election2026 | #ElectionWithPT | #TNElection
61
178
574
9
51K

Something went wrong.


Something went wrong.


United States Trends